{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:34:15Z","timestamp":1793522055546,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82250710684"],"award-info":[{"award-number":["82250710684"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02664-x","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:01:41Z","timestamp":1776384101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance"],"prefix":"10.1038","volume":"11","author":[{"given":"Zuming","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaishuai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6617","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2664_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","volume":"9","author":"N Yin","year":"2024","unstructured":"Yin, N. et al. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct. Target. Ther. 9, 126 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2664_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B. et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther. 9, 274 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2664_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"YT Liu","year":"2025","unstructured":"Liu, Y. T. et al. Turning cold tumors into hot tumors to ignite immunotherapy. Mol. Cancer 24, 254 (2025).","journal-title":"Mol. Cancer"},{"key":"2664_CR4","doi-asserted-by":"publisher","first-page":"1617773","DOI":"10.3389\/fimmu.2025.1617773","volume":"16","author":"GK Albert","year":"2025","unstructured":"Albert, G. K., Cao, P. & Davila, E. Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity. Front. Immunol. 16, 1617773 (2025).","journal-title":"Front. Immunol."},{"key":"2664_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014\u20131022 (2013).","journal-title":"Nat. Immunol."},{"key":"2664_CR6","doi-asserted-by":"crossref","unstructured":"Liu, Y., Xu, L., Dou, Y. & He, Y. AXL:shapers of tumor progression and immunosuppressive microenvironments. Mol. Cancer 24, 11 (2025).","DOI":"10.1186\/s12943-024-02210-9"},{"key":"2664_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cell.2007.10.034","volume":"131","author":"CV Rothlin","year":"2007","unstructured":"Rothlin, C. V. et al. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124\u20131136 (2007).","journal-title":"Cell"},{"key":"2664_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","volume":"10","author":"M Yadav","year":"2025","unstructured":"Yadav, M. et al. AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduct. Target. Ther. 10, 37 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2664_CR9","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","volume":"23","author":"HD Skinner","year":"2017","unstructured":"Skinner, H. D. et al. Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin. Cancer Res. 23, 2713\u20132722 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2664_CR10","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.1158\/1078-0432.CCR-21-0972","volume":"27","author":"S Terry","year":"2021","unstructured":"Terry, S. et al. Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade. Clin. Cancer Res. 27, 6749\u20136760 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2664_CR11","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00432-017-2408-4","volume":"143","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases. J. Cancer Res. Clin. Oncol. 143, 1947\u20131957 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2664_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/bjc.2015.237","volume":"113","author":"H Yu","year":"2015","unstructured":"Yu, H. et al. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br. J. Cancer 113, 616\u2013625 (2015).","journal-title":"Br. J. Cancer"},{"key":"2664_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s10120-020-01066-4","volume":"23","author":"CA Bae","year":"2020","unstructured":"Bae, C. A. et al. Inhibiting the GAS6\/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. Gastric Cancer 23, 824\u2013836 (2020).","journal-title":"Gastric Cancer"},{"key":"2664_CR14","doi-asserted-by":"crossref","unstructured":"Antony, J. et al. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Rep. 19, e45670 (2018).","DOI":"10.15252\/embr.201745670"},{"key":"2664_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3892\/ol.2016.5524","volume":"13","author":"G Jin","year":"2017","unstructured":"Jin, G. et al. Expression of Axl and its prognostic significance in human breast cancer. Oncol. Lett. 13, 621\u2013628 (2017).","journal-title":"Oncol. Lett."},{"key":"2664_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nm.4472","volume":"24","author":"J Boshuizen","year":"2018","unstructured":"Boshuizen, J. et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors. Nat. Med. 24, 203\u2013212 (2018).","journal-title":"Nat. Med."},{"key":"2664_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41571-023-00813-7","volume":"20","author":"D DeRyckere","year":"2023","unstructured":"DeRyckere, D., Huelse, J. M., Earp, H. S. & Graham, D. K. TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nat. Rev. Clin. Oncol. 20, 755\u2013779 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2664_CR18","doi-asserted-by":"publisher","first-page":"116475","DOI":"10.1016\/j.ejmech.2024.116475","volume":"272","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Recent discovery and development of AXL inhibitors as antitumor agents. Eur. J. Med. Chem. 272, 116475 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2664_CR19","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.7150\/thno.91456","volume":"14","author":"N Vandewalle","year":"2024","unstructured":"Vandewalle, N. et al. AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia. Theranostics 14, 2656\u20132674 (2024).","journal-title":"Theranostics"},{"key":"2664_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3892\/ol.2021.13010","volume":"22","author":"H Chang","year":"2021","unstructured":"Chang, H. et al. Anti-Axl monoclonal antibodies attenuate the migration of MDA-MB-231 breast cancer cells. Oncol. Lett. 22, 749 (2021).","journal-title":"Oncol. Lett."},{"key":"2664_CR21","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15140","volume":"9","author":"TJ Chen","year":"2021","unstructured":"Chen, T. J. et al. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiol. Rep. 9, e15140 (2021).","journal-title":"Physiol. Rep."},{"key":"2664_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/cts.12706","volume":"13","author":"L Bonifacio","year":"2020","unstructured":"Bonifacio, L. et al. Target-mediated drug disposition pharmacokinetic\/pharmacodynamic model-informed dose selection for the first-in-human study of AVB-S6-500. Clin. Transl. Sci. 13, 204\u2013211 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"2664_CR23","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1038\/onc.2010.268","volume":"29","author":"X Ye","year":"2010","unstructured":"Ye, X. et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254\u20135264 (2010).","journal-title":"Oncogene"},{"key":"2664_CR24","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1158\/1078-0432.CCR-16-1316","volume":"23","author":"W Leconet","year":"2017","unstructured":"Leconet, W. et al. Therapeutic activity of anti-AXL antibody against triple-negative breast cancer patient-derived xenografts and metastasis. Clin. Cancer Res. 23, 2806\u20132816 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2664_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","volume":"24","author":"F Galvez-Cancino","year":"2024","unstructured":"Galvez-Cancino, F. et al. Fc\u03b3 receptors and immunomodulatory antibodies in cancer. Nat. Rev. Cancer 24, 51\u201371 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2664_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1653708","volume":"12","author":"Z Yin","year":"2025","unstructured":"Yin, Z. et al. Detection of Gas6\/AXL complex and its expression changes in patients with ST-segment elevation myocardial infarction. Front. Med. 12, 1653708 (2025).","journal-title":"Front. Med."},{"key":"2664_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1022-2","volume":"18","author":"KV Myers","year":"2019","unstructured":"Myers, K. V., Amend, S. R. & Pienta, K. J. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol. Cancer 18, 94 (2019).","journal-title":"Mol. Cancer"},{"key":"2664_CR28","doi-asserted-by":"publisher","first-page":"a009076","DOI":"10.1101\/cshperspect.a009076","volume":"5","author":"G Lemke","year":"2013","unstructured":"Lemke, G. Biology of the TAM receptors. Cold Spring Harb. Perspect. Biol. 5, a009076 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2664_CR29","doi-asserted-by":"crossref","unstructured":"Rankin, E. B. & Giaccia, A. J. The receptor tyrosine kinase AXL in cancer progression. Cancers 8, 103 (2016).","DOI":"10.3390\/cancers8110103"},{"key":"2664_CR30","doi-asserted-by":"crossref","unstructured":"Khan, S. M. et al. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors. J. Immunother. Cancer 10, e005293 (2022).","DOI":"10.1136\/jitc-2022-005293"},{"key":"2664_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris, S. T. et al. cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature 584, 624\u2013629 (2020).","journal-title":"Nature"},{"key":"2664_CR32","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488\u20132496 (2011).","journal-title":"Cancer Res."},{"key":"2664_CR33","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"2664_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95157-6","volume":"11","author":"N de Queiroz","year":"2021","unstructured":"de Queiroz, N. et al. MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model. Sci. Rep. 11, 15648 (2021).","journal-title":"Sci. Rep."},{"key":"2664_CR35","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4161\/onci.21284","volume":"1","author":"T Mizutani","year":"2012","unstructured":"Mizutani, T. et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 1, 1027\u20131037 (2012).","journal-title":"Oncoimmunology"},{"key":"2664_CR36","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1182\/blood.2022016084","volume":"140","author":"S Li","year":"2022","unstructured":"Li, S. et al. IL-1\u03b2 expression in bone marrow dendritic cells is induced by TLR2 agonists and regulates HSC function. Blood 140, 1607\u20131620 (2022).","journal-title":"Blood"},{"key":"2664_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.immuni.2016.01.001","volume":"44","author":"JL Larson-Casey","year":"2016","unstructured":"Larson-Casey, J. L. et al. Macrophage Akt1 kinase-mediated mitophagy modulates apoptosis resistance and pulmonary fibrosis. Immunity 44, 582\u2013596 (2016).","journal-title":"Immunity"},{"key":"2664_CR38","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ccell.2018.05.009","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi, R. et al. Non-conventional inhibitory CD4(+)Foxp3(-)PD-1(hi) T cells as a biomarker of immune checkpoint blockade activity. Cancer Cell 33, 1017\u20131032.e1017 (2018).","journal-title":"Cancer Cell"},{"key":"2664_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","volume":"2","author":"HJ Kim","year":"2014","unstructured":"Kim, H. J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res. 2, 91\u201398 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2664_CR40","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","volume":"14","author":"KD Moynihan","year":"2024","unstructured":"Moynihan, K. D. et al. IL2 Targeted to CD8+ T cells promotes robust effector T-cell responses and potent antitumor immunity. Cancer Discov. 14, 1206\u20131225 (2024).","journal-title":"Cancer Discov."},{"key":"2664_CR41","doi-asserted-by":"crossref","unstructured":"Ren, Z. et al. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. J. Clin. Investig. 132, e153604 (2022).","DOI":"10.1172\/JCI153604"},{"key":"2664_CR42","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1182\/blood-2008-11-190827","volume":"113","author":"W Jing","year":"2009","unstructured":"Jing, W., Gershan, J. A. & Johnson, B. D. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood 113, 4449\u20134457 (2009).","journal-title":"Blood"},{"key":"2664_CR43","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.4049\/jimmunol.1601473","volume":"198","author":"KLS Cleary","year":"2017","unstructured":"Cleary, K. L. S. et al. Antibody distance from the cell membrane regulates antibody effector mechanisms. J. Immunol. 198, 3999\u20134011 (2017).","journal-title":"J. Immunol."},{"key":"2664_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.bbrc.2008.11.033","volume":"378","author":"K Nakano","year":"2009","unstructured":"Nakano, K. et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 378, 279\u2013284 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2664_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser, N. E. et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat. Commun. 14, 1394 (2023).","journal-title":"Nat. Commun."},{"key":"2664_CR46","doi-asserted-by":"publisher","first-page":"112612","DOI":"10.1016\/j.intimp.2024.112612","volume":"138","author":"J Panaampon","year":"2024","unstructured":"Panaampon, J. et al. Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms. Int. Immunopharmacol. 138, 112612 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"2664_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1739408","volume":"12","author":"E Hatterer","year":"2020","unstructured":"Hatterer, E. et al. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. MAbs 12, 1739408 (2020).","journal-title":"MAbs"},{"key":"2664_CR48","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","volume":"7","author":"JO Richards","year":"2008","unstructured":"Richards, J. O. et al. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7, 2517\u20132527 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"2664_CR49","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.immuni.2025.05.008","volume":"58","author":"M W\u00f6hner","year":"2025","unstructured":"W\u00f6hner, M. & Nimmerjahn, F. Cytotoxic IgG: mechanisms, functions, and applications. Immunity 58, 1378\u20131395 (2025).","journal-title":"Immunity"},{"key":"2664_CR50","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1073\/pnas.1423356112","volume":"112","author":"CA Bernhard","year":"2015","unstructured":"Bernhard, C. A., Ried, C., Kochanek, S. & Brocker, T. CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells. Proc. Natl. Acad. Sci. USA 112, 5461\u20135466 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2664_CR51","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1172\/JCI97642","volume":"129","author":"D Muraoka","year":"2019","unstructured":"Muraoka, D. et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J. Clin. Investig. 129, 1278\u20131294 (2019).","journal-title":"J. Clin. Investig."},{"key":"2664_CR52","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.4049\/jimmunol.2100222","volume":"207","author":"H Abberger","year":"2021","unstructured":"Abberger, H. et al. Neuropilin-1 is expressed on highly activated CD4(+) effector T cells and dysfunctional CD4(+) conventional T cells from naive mice. J. Immunol. 207, 1288\u20131297 (2021).","journal-title":"J. Immunol."},{"key":"2664_CR53","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s41590-023-01611-0","volume":"24","author":"PS Liu","year":"2023","unstructured":"Liu, P. S. et al. Author Correction: CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat. Immunol. 24, 1591 (2023).","journal-title":"Nat. Immunol."},{"key":"2664_CR54","first-page":"145","volume":"8","author":"HW Chang","year":"2025","unstructured":"Chang, H. W. et al. Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate. Antib. Ther. 8, 145\u2013156 (2025).","journal-title":"Antib. Ther."},{"key":"2664_CR55","doi-asserted-by":"publisher","first-page":"4.22.21","DOI":"10.1002\/0471142727.mb0422s107","volume":"107","author":"JJ Trombetta","year":"2014","unstructured":"Trombetta, J. J. et al. Preparation of single-cell RNA-seq libraries for next generation sequencing. Curr. Protoc. Mol. Biol. 107, 4.22.21\u201324.22.17 (2014).","journal-title":"Curr. Protoc. Mol. Biol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02664-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02664-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02664-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:01:42Z","timestamp":1776384102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02664-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02664-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.Z., X.N., Z.Y., and L.Z. are listed as inventors on a patent application (Patent Application Number: CN2024115456701) for anti-AXL antibodies. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}